Kazia Therapeutics Ltd
KZIA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001075880
No open-market purchases or sales by Kazia Therapeutics Ltd insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $50.7M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Kazia Therapeutics Ltd changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 14 | 15 | +1 |
| Shares | 467.1K | 536.3K | +69.3K (+14.8%) |
| Value | $4.60M | $4.35M | −$255.3K (−5.5%) |
New holders (4)
Institutions that held Kazia Therapeutics Ltd at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ACT Capital Management, LLC | 25,000 | $247.0K | 0.13% |
| Citadel Advisors LLC | 12,778 | $126.0K | 0.00% |
| Simplex Trading, LLC | 4,583 | $45.0K | 0.00% |
| JPMorgan Chase & Co | 10 | $0 | 0.00% |
Sold out (3)
Institutions that held Kazia Therapeutics Ltd at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Susquehanna Fundamental Investments, LLC | 11,600 | $144.0K |
| Total Clarity Wealth Management, Inc. | 1,790 | $22.0K |
| UBS Group AG | 1,616 | $20.0K |